272 related articles for article (PubMed ID: 27612952)
21. Advances in the management of cutaneous toxicities of targeted therapies.
Robert C; Sibaud V; Mateus C; Cherpelis BS
Semin Oncol; 2012 Apr; 39(2):227-40. PubMed ID: 22484194
[TBL] [Abstract][Full Text] [Related]
22. Side effects of targeted therapies: rash.
Eaby-Sandy B; Lynch K
Semin Oncol Nurs; 2014 Aug; 30(3):147-54. PubMed ID: 25085026
[TBL] [Abstract][Full Text] [Related]
23. Arterial Thrombotic Complications of Tyrosine Kinase Inhibitors.
Wu MD; Moslehi JJ; Lindner JR
Arterioscler Thromb Vasc Biol; 2021 Jan; 41(1):3-10. PubMed ID: 33275447
[TBL] [Abstract][Full Text] [Related]
24. Vascular effects of cancer treatments.
Campia U
Vasc Med; 2020 Jun; 25(3):226-234. PubMed ID: 32539632
[TBL] [Abstract][Full Text] [Related]
25. Ocular adverse events of molecularly targeted agents approved in solid tumours: a systematic review.
Huillard O; Bakalian S; Levy C; Desjardins L; Lumbroso-Le Rouic L; Pop S; Sablin MP; Le Tourneau C
Eur J Cancer; 2014 Feb; 50(3):638-48. PubMed ID: 24256808
[TBL] [Abstract][Full Text] [Related]
26. [Management of adverse effects of targeted therapy toxicities in oncology].
Coquan E; Henri P; de Raucourt S; Lireux B; Lamy E; Delcambre C; Sevin E; Dutriaux C; Bouhier-Leporrier K; Gervais R; Joly F
Rev Prat; 2012 Jan; 62(1):17-25. PubMed ID: 22335060
[TBL] [Abstract][Full Text] [Related]
27. Alopecia in patients treated with molecularly targeted anticancer therapies.
Belum VR; Marulanda K; Ensslin C; Gorcey L; Parikh T; Wu S; Busam KJ; Gerber PA; Lacouture ME
Ann Oncol; 2015 Dec; 26(12):2496-502. PubMed ID: 26387145
[TBL] [Abstract][Full Text] [Related]
28. The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients.
Hall PS; Harshman LC; Srinivas S; Witteles RM
JACC Heart Fail; 2013 Feb; 1(1):72-8. PubMed ID: 24621801
[TBL] [Abstract][Full Text] [Related]
29. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
Ali MA
Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
[TBL] [Abstract][Full Text] [Related]
30. [Renal toxicity of anti-VEGF (corrected) targeted therapies].
Vigneau C; Rioux-Leclercq N
Nephrol Ther; 2013 Jun; 9(3):174-9. PubMed ID: 23410950
[TBL] [Abstract][Full Text] [Related]
31. Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors.
Steingart RM; Bakris GL; Chen HX; Chen MH; Force T; Ivy SP; Leier CV; Liu G; Lenihan D; Lindenfeld J; Maitland ML; Remick SC; Tang WH
Am Heart J; 2012 Feb; 163(2):156-63. PubMed ID: 22305831
[TBL] [Abstract][Full Text] [Related]
32. Metabolic disorders associated with the use of targeted cancer therapies.
Kotecki N; Penel N; Awada A
Curr Opin Oncol; 2015 May; 27(3):258-66. PubMed ID: 25730544
[TBL] [Abstract][Full Text] [Related]
33. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
34. Ocular toxicities of MEK inhibitors and other targeted therapies.
Stjepanovic N; Velazquez-Martin JP; Bedard PL
Ann Oncol; 2016 Jun; 27(6):998-1005. PubMed ID: 26951625
[TBL] [Abstract][Full Text] [Related]
35. Cardiotoxic effects of chemotherapy: A review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system.
Babiker HM; McBride A; Newton M; Boehmer LM; Drucker AG; Gowan M; Cassagnol M; Camenisch TD; Anwer F; Hollands JM
Crit Rev Oncol Hematol; 2018 Jun; 126():186-200. PubMed ID: 29759560
[TBL] [Abstract][Full Text] [Related]
36. Adverse events of targeted therapies.
Klastersky JA
Curr Opin Oncol; 2014 Jul; 26(4):395-402. PubMed ID: 24825019
[TBL] [Abstract][Full Text] [Related]
37. Science and mechanism of action of targeted therapies in cancer treatment.
Wujcik D
Semin Oncol Nurs; 2014 Aug; 30(3):139-46. PubMed ID: 25085025
[TBL] [Abstract][Full Text] [Related]
38. Molecular Targeted Therapy in Modern Oncology: Imaging Assessment of Treatment Response and Toxicities.
Krajewski KM; Braschi-Amirfarzan M; DiPiro PJ; Jagannathan JP; Shinagare AB
Korean J Radiol; 2017; 18(1):28-41. PubMed ID: 28096716
[TBL] [Abstract][Full Text] [Related]
39. Managing Cutaneous Side Effects From Targeted Molecular Inhibitors for Melanoma and Nonmelanoma Skin Cancer.
Tang N; Ratner D
Dermatol Surg; 2016 Jan; 42 Suppl 1():S40-8. PubMed ID: 26730973
[TBL] [Abstract][Full Text] [Related]
40. Onconephrology: What Should the Internist Know About Targeted Therapy in Solid Tumors?
El Rassy E; El Karak F; Rizkallah J; Chelala D
Iran J Kidney Dis; 2016 Jul; 10(4):169-75. PubMed ID: 27514761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
